

Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

CD44 Antibody, anti-human, PE, REAfinity™

RRID:AB_2726395

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-904, RRID:AB_2726395

Antibody Information

URL: http://antibodyregistry.org/AB_2726395

Proper Citation: Miltenyi Biotec Cat# 130-113-904, RRID:AB_2726395

Target Antigen: CD44

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-394. (RRID:AB_2658164).

Antibody Name: CD44 Antibody, anti-human, PE, REAfinity™

Description: This monoclonal targets CD44

Target Organism: human

Clone ID: clone REA690

Antibody ID: AB_2726395

Vendor: Miltenyi Biotec

Catalog Number: 130-113-904

Record Creation Time: 20250820T022438+0000

Record Last Update: 20250820T133054+0000

Ratings and Alerts

No rating or validation information has been found for CD44 Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD44 Antibody, anti-human, PE, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. iScience, 27(3), 108794.